‘Michael’ overtakes ‘Bohemian Rhapsody’ with $911.9M worldwide, becoming top-grossing music biopic

Michael has officially taken the crown in a way that makes studios sit up straight: Deadline reports the Freddie Mercury biopic Bohemian Rhapsody has been dethroned as the highest-grossing music biopic of all time by Michael, which has reached $911.9M worldwide. In other words, the market has spoken, and it didn’t whisper.

This is not just a fun entertainment trivia moment. The all-time rank matters because it is shorthand for how audiences, critics, and theatrical calendars are aligning for a specific kind of product. Deadline frames the development as a landslide, and it points directly to the economics: the King of Pop’s biopic, Michael, has now become the top performer in its category at $911.9M worldwide, surpassing Bohemian Rhapsody. Lionsgate and Universal are the key studio players behind this win, and that matters if you are evaluating risk, slate strategy, and how aggressively you should greenlight similar projects.

To understand why this figure is such a big deal, zoom out to how music biopics typically behave in the marketplace. A biopic is expensive enough to demand serious upside, but it is also a category with built-in audience gravity. The appeal is rarely generic; it’s anchored to a cultural figure, a catalog of recognizable songs, and a built-in story engine that audiences already have emotional context for. When a studio can claim “highest-grossing of all time” status at $911.9M, it changes internal conversations fast. Marketing budgets get easier to justify. Distribution confidence gets sharper. Execs with slate responsibility can point to a benchmark that reads like proof-of-demand.

It also changes how boards and investors think about sequencing. The headline you clicked implies a clear winner, but the deeper story is timing. Bohemian Rhapsody was the reference point, and now Michael is the new one. In studio land, these references shape how quickly competitors react. If you are sitting in a boardroom, you are not just asking “did it make money?” You are asking “what does this recalibrate?” If audiences will go all-in again for this format, then the opportunity cost of delaying another biopic drops. The upside of momentum becomes measurable, not theoretical.

There is also a broader industry implication here: theatrical performance rankings can influence downstream windows and partner negotiations. A top-grossing film tends to carry leverage across home entertainment, streaming license conversations, and brand partnerships tied to the film’s lifecycle. Even when studios do not reveal segment-level economics, the market uses gross totals as a proxy for consumer pull. That is why a clean category dethroning can create ripple effects beyond the initial release.

Finally, this is a reminder that music biopics sit at the intersection of culture and business. The Deadline framing explicitly ties the result to both Michael and Janet Jackson’s world, and it puts the spotlight on the “King of Pop’s biopic” as the engine behind the new record. That matters for decision-makers because it underscores what actually sells: not only famous names, but the narrative focus audiences connect to. When the category’s top performer rotates, it suggests that story framing and audience emotional alignment can matter as much as production scale.

For peers evaluating similar slates, the strategic stake is straightforward. If Michael can hit $911.9M worldwide and seize the all-time music biopic title, then future greenlights will face a higher bar, and the debate will tilt toward projects with similarly strong “built-in” audience demand. Lionsgate and Universal now have a new headline benchmark to defend in internal capital allocation conversations, and competitors will have to answer whether they can match the combination of cultural gravity, theatrical draw, and category positioning that drove this dethroning.